1. Search Result
Search Result
Results for "

pro-drug

" in MedChemExpress (MCE) Product Catalog:

225

Inhibitors & Agonists

7

Peptides

1

Inhibitory Antibodies

4

Natural
Products

6

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117630

    Drug Intermediate Cancer
    RB-6145 is an orally active pro-drug of the hypoxic cell radiosensitizer RSU 1069. RB-6145 acts a hypoxic cell radiosensitizer and cytotoxin but reduces systemic toxicity in mice .
    RB-6145
  • HY-163849

    Others Inflammation/Immunology
    Mizoribine prodrug-1 (compound 18) is a oral active ester-based mizoribine (HY-17470) prodrug. Mizoribine prodrug-1 displays a inhibition of IL-2 production .
    Mizoribine prodrug-1
  • HY-163850

    Interleukin Related Inflammation/Immunology
    Mizoribine prodrug-2 trifluoroacetate (compound 20) is a oral active mizoribine (HY-17470) prodrug (amino acid conjugate). Mizoribine prodrug-2 displays a prolonged inhibition of IL-2 production .
    Mizoribine prodrug-2 trifluoroacetate
  • HY-161336

    Bacterial Cancer
    Alendronate prodrug-1(compound 2) is an inhibitor of farnesyl diphosphate synthase (FPPS). Alendronate prodrug-1 has an antiproliferative effect with an IC50 value of 34.0 μM .
    Alendronate prodrug-1
  • HY-172813

    Bacterial Antibiotic Autophagy Infection Cancer
    Vancomycin prodrug (compound 13c) is a Vancomycin (HY-B0671) prodrug. Vancomycin prodrug shows antibacterial effect with MICs of 0.78 μM, 0.78 μM, 1.56 μM for S. aureus 330041, MRSA USA 300 and MRSA 3390, respectively. Vancomycin prodrug has the ability to quickly bind to Cys-34 residue of plasma. Vancomycin prodrug exhibits a good therapeutic effect on MRSA USA300 infected mice similar to Vancomycin. Vancomycin prodrug, an albumin-binding acid-sensitive prodrug, effectively reduces Vancomycin’s nephrotoxicity while maintaining its efficacy for Gram-positive bacterial infections .
    Vancomycin prodrug
  • HY-172148

    Interleukin Related Inflammation/Immunology
    Itaconic acid prodrug-1 (Compound P2) is an orally active prodrug of Itaconic acid (HY-Y0520) that efficiently delivers the active ingredient Itaconic acid to skin tissue following oral administration. Itaconic acid prodrug-1 possesses immunomodulatory properties, significantly inhibiting Poly(I:C)/IFNγ-induced inflammatory cytokines in human epidermal keratinocytes. Itaconic acid prodrug-1 can be utilized for the research of alopecia areata and other inflammatory skin diseases .
    Itaconic acid prodrug-1
  • HY-168928

    Bacterial Infection
    Antibiofilm agent prodrug 1 (Compound 5c) exhibits antibacterial activity through inhibition of biofilm formation and iron uptake. Antibiofilm agent prodrug 1 inhibits P. aeruginosa PAO1 with a MIC of 1.07 μM. Antibiofilm agent prodrug 1 exhibits anti-infectious efficacy in C. elegans with improved survival rate .
    Antibiofilm agent prodrug 1
  • HY-168875

    TrxR Reactive Oxygen Species (ROS) Cancer
    TrxR1 prodrug-1 (compound 5u) is a potent inhibitor of TrxR1. TrxR1 prodrug-1 exhibits significant antitumor efficiency in nude mice and NSCLC organoids .
    TrxR1 prodrug-1
  • HY-168472

    SARS-CoV Infection
    13-TP prodrug (compound 15) is a potent and orally active anti-SARS-CoV-2 agent. 13-TP prodrug shows cytotoxicity. 13-TP prodrug decreases the SARS-CoV-2 N protein expression. 13-TP prodrug shows antiviral activity .
    13-TP prodrug
  • HY-163544

    Others Cancer
    δ-Tocotrienol prodrug-1 (compound 5b) is a prodrug of δ-tocotrienol (HY-122778). δ-Tocotrienol prodrug-1 shows radioprotective efficacy. δ-Tocotrienol prodrug-1 promotes the hematopoietic progenitor and stem cell regeneration in murine bone marrow and spleen .
    δ-Tocotrienol prodrug-1
  • HY-173023

    Apoptosis Indoleamine 2,3-Dioxygenase (IDO) Reactive Oxygen Species (ROS) Cancer
    IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394) .
    IDOi-Pt(IV) prodrug-1
  • HY-176149

    CaMK MMP AMPK Apoptosis Autophagy Cancer
    Fluoxetine-Conjugated Platinum(IV) prodrug-1 (Compound 8) is an eEF2K inhibitor. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits cancer cell proliferation, induces DNA damage, cell cycle arrest at S phase and apoptosis. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces ROS accumulation and mitochondrial dysfunction. Fluoxetine-Conjugated Platinum(IV) prodrug-1 inhibits TNBC cell migration and invasion by inhibiting MMP-2 activity. Fluoxetine-Conjugated Platinum(IV) prodrug-1 induces autophagy in TNBC cells by activating AMPK. Fluoxetine-Conjugated Platinum(IV) prodrug-1 has antitumor activity and activates immunosuppression in the 4T1-Luc mouse model. Fluoxetine-Conjugated Platinum(IV) prodrug-1 can be used in triple-negative breast cancer (TNBC) research .
    Fluoxetine-Conjugated Platinum(IV) prodrug-1
  • HY-161687

    Src Cancer
    Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .
    Cisplatin/Dasatinib prodrug-1
  • HY-169131

    AMPK Cancer
    ALKBH1-IN-4 prodrug (Compound 29E) is a prodrug of a DNA N6-methyladenine demethylase ALKBH1 inhibitor that significantly increases the abundance of 6mA in cells and upregulates the AMPK signaling pathway, thereby inhibiting the viability of gastric cancer cells. ALKBH1-IN-4 prodrug exhibits excellent cellular activity and favorable metabolic exposure in vivo, and holds promise for research in gastric cancer .
    ALKBH1-IN-3 prodrug
  • HY-159921

    Microtubule/Tubulin Cancer
    Tubulin Polymerization-IN-1 prodrug (Compound 2b) is a palladium (Pd)-mediated tubulin polymerization inhibitor prodrug. Developed based on colchicine binding site inhibitors (CBSIs), it reduces toxicity and enhances targeted release properties. Compared to the parent compound, Tubulin Polymerization-IN-1 prodrug exhibited 68.3-fold lower cytotoxicity, which can be restored in situ in the presence of Pd resin. Mechanistic studies showed that its anticancer activity is consistent with CBSIs. In vivo, Tubulin Polymerization-IN-1 prodrug significantly inhibited tumor growth (63.2%) when activated by Pd resin. It holds promise for research in the field of anticancer therapy .
    Tubulin Polymerization-IN-1 prodrug
  • HY-10127A

    AZD1152 dihydrochloride

    Aurora Kinase Apoptosis Cancer
    Barasertib (AZD1152 dihydrochloride), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152 dihydrochloride) induces growth arrest and apoptosis in cancer cells .
    Barasertib dihydrochloride
  • HY-10127
    Barasertib
    Maximum Cited Publications
    18 Publications Verification

    AZD1152

    Aurora Kinase Apoptosis Cancer
    Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells .
    Barasertib
  • HY-100085

    21-desDFZ

    Drug Metabolite Inflammation/Immunology
    21-Desacetyldeflazacort (21-desDFZ) is the active metabolite of Deflazacort (HY-13609). Deflazacort is an anti-inflammatory and immunosuppressant. Deflazacort is an inactive pro-drug which can be rapidly converted by esterases to the active metabolite 21-desacetyldeflazacort after oral administration .
    21-Desacetyldeflazacort
  • HY-10127R

    AZD1152 (Standard)

    Reference Standards Aurora Kinase Apoptosis Cancer
    Barasertib (Standard) is the analytical standard of Barasertib. This product is intended for research and analytical applications. Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells .
    Barasertib (Standard)
  • HY-171030

    Ferroptosis Cancer
    Pro-GA is a γ-Glutamylcyclotransferase (GGCT) inhibitor and a cell-permeable diester-type pro-drug with anticancer activity, GGCT is a key enzyme in glutathione metabolism and is involved in the ferroptosis pathway. Pro-GA exhibits an IC50 of 57 μM against the bladder cancer cell line T24 and can be utilized in cancer research .
    Pro-GA
  • HY-107345

    Ombolan

    Prostaglandin Receptor Inflammation/Immunology
    Droxicam (Ombolan) is a non-steroidal anti-inflammatory agent, with strong analgesic activity. Droxicam acts by inhibiting PGE2 varies, and is characterised by being a pro-drug of Piroxicam (HY-B0253). Droxicam is well tolerated with slight side effects in the said mucosa. Droxicam does not show cardiovascular or respiratory effects in cats, and inhibits peritoneal capillary permeability in mouse .
    Droxicam
  • HY-100085R

    21-desDFZ (Standard)

    Drug Metabolite Reference Standards Inflammation/Immunology
    21-Desacetyldeflazacort (Standard) is the analytical standard of 21-Desacetyldeflazacort. This product is intended for research and analytical applications. 21-Desacetyldeflazacort (21-desDFZ) is the active metabolite of Deflazacort (HY-13609). Deflazacort is an anti-inflammatory and immunosuppressant. Deflazacort is an inactive pro-drug which can be rapidly converted by esterases to the active metabolite 21-desacetyldeflazacort after oral administration .
    21-Desacetyldeflazacort (Standard)
  • HY-149025

    P18

    Phospholipase Inflammation/Immunology Cancer
    DPTIP-proagent 18 (P18) is a orally active and brain-penetrable proagent of DPTIP (HY-131002). DPTIP-proagent 18 is a potent nSMase2 inhibitor. DPTIP-proagent 18 significantly inhibits IL-1β-induced EV (extracellular vesicle) release by inhibition of nSMase2 (neutral sphingomyelinase-2) activity. DPTIP-proagent 18 can be used for brain injury research .
    DPTIP-prodrug 18
  • HY-168635

    PROTACs Epigenetic Reader Domain Cancer
    SJ46420, a SJ46421 (HY-168634) pro-drug variant, is a potent and selective BRD3 PROTAC degrader. SJ46420 degrads BRD3 in a KLHDC2-dependent manner, thereby partially reducing the levels of BRD2 or BRD4 (Pink: ligand for target protein (HY-13030); Black: linker (HY-20797); Blue: E3 ligase ligand (HY-159973)) .
    SJ46420
  • HY-139995

    Drug Intermediate Others
    Spermine precursor-1 (Compound 1) is a redox-sensitive spermine precursor for the potential research of snyder robinson syndrome. Spermine precursor-1 inhibits wild-type (CMS-24949) and spermine synthase gene (SMS) mutant (CMS-26559, and CMS-6233) fibroblast cells with IC50s of 326.7, 198.5, and 244.1 μM, respectively .
    Spermine Prodrug-1
  • HY-145829

    JAK Apoptosis Inflammation/Immunology
    Tofacitinib precursor-1 is an effective and oral active precursor to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib precursor-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity. Tofacitinib precursor-1 is a potential drug candidate for the research of ulcerative colitis .
    Tofacitinib Prodrug-1
  • HY-145323

    Biochemical Assay Reagents Cancer
    Mitochondria-Targeted Photoactivatable Proagent accumulates in the mitochondria and shows light-triggered temporally controlled cell death. Mitochondria-Targeted Photoactivatable Proagent can be used in a novel drug delivery platform that provides on-demand, real-time, organelle-specific agent release and monitoring upon photoactivation .
    Mitochondria-Targeted Photoactivatable Prodrug
  • HY-121398

    Adrenergic Receptor Endogenous Metabolite Others
    Dipivefrin is a potent adrenergic agonist. Dipivefrin is an adrenergic pro-agent. Dipivefrin can be used for reduce IOP (intraocular pressure) in patients suffering from chronic open angle glaucoma .
    Dipivefrin
  • HY-168639

    Mitochondrial Metabolism AMPK Metabolic Disease
    AP39 prodrug 1 (Compound M1) is a mitochondria-targeted H2S prodrug. AP39 prodrug 1 induces ROS-dependent mild mitochondrial uncoupling, activating mitochondria-associated AMPK to suppress Palmitic acid (PA) (HY-N0830)-induced lipid deposition in hepatocytes .
    AMPK activator 15
  • HY-Z4483

    Drug Intermediate Others
    6-Deoxypenciclovir is an inactive metabolite of the antiviral prodrug Famciclovir. 6-Deoxypenciclovir is a good substrate for rabbit hepatic aldehyde oxidase and can be used to synthesize the prodrug form of penciclovir .
    6-Deoxypenciclovir
  • HY-W342471

    Drug Intermediate Neurological Disease
    Nordiazepam uncyclized intermediate hydrochloride is a prodrug form of Nordiazepam.
    Nordiazepam uncyclized intermediate hydrochloride
  • HY-A0032

    CMV Infection Cancer
    Valganciclovir, the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir.
    Valganciclovir
  • HY-163486

    Bacterial Infection
    Antituberculosis agent-10 (Compound 9) has excellent antibacterial activity against Mycobacterium tuberculosis (MIC = 0.3 μM). Antituberculosis agent-10 inhibits protein synthesis by targeting the 50S ribosomal subunit of the bacterium, thus exerting its antibacterial effect. Antituberculosis agent-10 is orally active .
    Antituberculosis agent-10
  • HY-B1149A

    Bacterial Antibiotic Infection
    Bacampicillin hydrochloride is a penicillin antibiotic, is a prodrug of ampicillin with improved oral bioavailability.
    Bacampicillin hydrochloride
  • HY-127122

    HBV Infection
    Valtorcitabine dihydrochloride is a prodrug of L-deoxycytidine and also is an HBV inhibitor .
    Valtorcitabine dihydrochloride
  • HY-109755

    Bacterial Antibiotic Others
    PF-04064900 is a prodrug of sulopenem penem antibiotic .
    PF-04064900
  • HY-B1149

    Bacterial Antibiotic Infection
    Bacampicillin is a penicillin antibiotic, is a prodrug of ampicillin with improved oral bioavailability.
    Bacampicillin
  • HY-162410

    MDM-2/p53 Cancer
    Fluplatin is a prodrug composed of cisplatin and fluvastatin. Fluplatin has antitumor activity .
    Fluplatin
  • HY-118983

    Antibiotic Bacterial Infection
    Pivampicillin hydrochloride is a penicillin antibiotic. Pivampicillin hydrochloride is a prodrug of Ampicillin (HY-B0522) .
    Pivampicillin hydrochloride
  • HY-169855

    Drug Intermediate Others
    Apaziquone hydroquinone is a bioreductive prodrug and a derivative of Mitomycin C (HY-13316) .
    Apaziquone hydroquinone
  • HY-137238

    Drug Metabolite Metabolic Disease
    Ethyl mycophenolate is a potential impurity found in commercial preparations of the mycophenolic acid prodrug mycophenolate mofetil.
    Ethyl mycophenolate
  • HY-119011

    Antibiotic Bacterial Infection
    Pivampicillin is a penicillin antibiotic. Pivampicillin is a prodrug of Ampicillin (HY-B0522) .
    Pivampicillin
  • HY-162448

    Others Inflammation/Immunology
    SerBut is a serine conjugated butyrate prodrug with oral activity. SerBut has anti-inflammatory activity .
    SerBut
  • HY-12758

    BCRP Cancer
    YHO-13351 is the prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP.
    YHO-13351
  • HY-155371

    PROTACs Others
    BT-PROTAC is a bioorthogonally activatable prodrug. BT-PROTAC can accurately control the activity of PROTAC .
    BT-PROTAC
  • HY-17357

    AHR 9434; AL 6515

    COX Bacterial Inflammation/Immunology
    Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac.
    Nepafenac
  • HY-105929

    17-Monochloroacetylajmaline

    Sodium Channel Cardiovascular Disease
    Lorajmine (17-Monochloroacetylajmaline) is an Ajmaline (HY-B1167) (Sodium channel blocker) prodrug .
    Lorajmine
  • HY-19495

    Endogenous Metabolite Others
    OT-730 is an innovative selective beta-blocker prodrug designed for research into ocular diseases.
    OT-730
  • HY-125868

    Antibiotic Bacterial Infection
    Penethamate hydriodide is a diethylaminoethyl ester prodrug of benzylpenicillin that can be used to treat bovine mastitis via the intramuscular route .
    Penethamate hydriodide
  • HY-B1079

    Drug Intermediate Inflammation/Immunology
    Suxibuzone is a compound used for the study of joint and muscle pain, and it is a prodrug of the non-steroidal anti-inflammatory drug Phenylbutazone.
    Suxibuzone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: